<DOC>
	<DOC>NCT01850355</DOC>
	<brief_summary>The main objective of this exploratory 8-week pilot study is to evaluate the safety and efficacy of buspirone for the treatment of anxiety in youth (ages 6-17 years) with autism spectrum disorders. The study results will be used to generate hypothesis for a larger randomized controlled clinical trials with explicit hypotheses and sufficient statistical power.</brief_summary>
	<brief_title>An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders, Pervasive</mesh_term>
	<mesh_term>Buspirone</mesh_term>
	<criteria>Male or female participants between 6 and 17 years of age Fulfills diagnosis of autism spectrum disorders by meeting DSMIVTR PDD diagnostic criteria of autistic disorder, Asperger's disorder, or PDDNOS as established by clinical diagnostic interview Participants with a score of ≥13 on the Pediatric Anxiety Rating Scale (PARS) Participants with a score of ≥60 or more on the Anxiety/Depression subscale of CBCL and CGIAnxiety severity of ≥ 4 Subjects can be on psychotropic drugs if they have been on the medication for at least 4 weeks prior to initiating trial treatment and if they are stable, provided the medication is not listed in the Concomitant Medications section of the protocol. Subjects with disruptive behavior disorders, mood, or psychosis will be allowed to participate in the study provided they do not meet any exclusionary criteria I.Q. &lt; 70 DSMIVTR PDD diagnoses of Rett's disorder, and childhood disintegrative disorder History of active seizure disorder (EEG suggestive of seizure activity and/or history of seizure in last 1 month) Subjects with a medical condition or treatment that will either jeopardize subject safety or affect the scientific merit of the study, including: Pregnant or nursing females Organic brain disorders Uncorrected hypothyroidism or hyperthyroidism Clinically significant abnormalities on ECG (e.g., QT prolongation, arrhythmia) History of renal or hepatic impairment Clinically unstable psychiatric conditions or judged to be at serious suicidal risk Current diagnosis of schizophrenia History of substance use (except nicotine or caffeine) within past 3 months or urine drug screen positive for substances of abuse Current treatment with medication with primary central nervous system activity (as specified in the Concomitant Medication section of the protocol) A nonresponder or history of intolerance to buspirone, after treatment at an adequate dose and duration as determined by the clinician Subjects currently taking monoamine oxidase inhibitors (MAOI) and/or CYP3A4 inducers or inhibitors including nefazodone, diltiazem, verapamil, erythromaycin, itraconazole, or rifampin.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Autism Spectrum Disorders</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Buspar</keyword>
	<keyword>Buspirone</keyword>
	<keyword>Pervasive Developmental Disorders</keyword>
</DOC>